Hemispherx fatigue drug Ampligen rejected for approval, WSJ reports An FDA panel voted 8-to-5 against approval of Hemixpherx's (HEB) chronic fatigue drug Ampligen at an FDA Arthritis Advisory Committee Meeting Thursday, according to a Wall Street Journal report. Reference Link
News For HEB From The Last 14 Days
Check below for free stories on HEB the last two weeks.
Hemispherx, University of Pittsburgh collaborate on Chemokine Modulation program Hemispherx Biopharma announced that it is supporting the University of Pittsburgh's National Institutes of Health funded study currently underway as part of the University's Chemokine Modulation Research initiative which includes Ampligen as an adjuvant. As part of this collaboration, Hemispherx has supplied clinical grade Ampligen to the University. This collaboration expands the company's current collaborations with several other comprehensive cancer care centers conducting preclinical and clinical research into the modulation of cancer immunity to discover the best ways to activate the immune system to recognize and eradicate cancer. Ampligen is an experimental Toll Like Receptor 3 agonist with immune modulatory properties that modify the character of patient's immunity.